Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds

A method of treating diabetic nephropathy;

• the method comprises the steps of first identifying a subject suffering from diabetic nephropathy, then administering to the subject an effective amount of a compound of Formula II to treat diabetic nephropathy;
• wherein:
• Q is (CR4R5)n3;
• n1 is 1;
• n2 is 1;
• n3 is 1, 2, or 3;
• R2 is R2-2:
• Ar is a monocyclic aryl or bicyclic aryl;
• X is from 1 to 3 substituents on Ar, and each is independently selected from the group consisting of OR8, NR8R9, SR8, SO2NR8R9, NR8SO2R9, CONR8R9, NR8C(═O)R9, NR8C(═O)OR9, OC(═O)NR8R9, and NR8C(═O)NR9R10;
• R3 is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, or cycloalkylalkynyl, optionally substituted;
• R4 and R5 are H;
• R8-R10 are independently H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, (heterocycle)alkyl, (heterocycle)alkenyl, (heterocycle)alkynyl, or heterocycle;
• optionally substituted by one or more halogen or heteroatom-containing substituents selected from the group consisting of OR11, NR11R12, NO2, SR11, SOR11, SO2R11, SO2NR11R12, NR11SO2R12, OCF3, CONR11R12, NR11C(═O)R12, NR11C(═O)OR12, OC(═O)NR11R12, and NR11C(═O)NR12R13;
• R11-R13 are independently H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, (heterocycle)alkyl, (heterocycle)alkenyl, (heterocycle)alkynyl, or heterocycle;
• with the proviso that if X is acyclic and is connected to Ar by an oxygen or nitrogen atom, then X contains at least one additional oxygen, nitrogen or sulfur atom.